RJA
ONCT

Raymond James & Associates’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Raymond James & Associates’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-23
Closed -$215K – 1997
2013
Q2 		$215K Buy
+23
New +$177K ﹤0.01% 1829

Other funds holding ONCT

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Raymond James & Associates's ONCT Position: Q3 2013 in Review

Raymond James & Associates sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2013, closing a stake of 23 shares — an estimated $215K sold.

Raymond James & Associates first reported a position in ONCT in Q2 2013 and held it in 1 quarter. The position peaked at $215K in Q2 2013. 58 funds tracked by Wall St. Rank hold ONCT as of Q3 2013.

  • Raymond James & Associates reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2013 after selling out during the quarter.
  • Raymond James & Associates sold 23 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2013, an estimated $215K.
  • Raymond James & Associates first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 1 quarter.
  • Raymond James & Associates's Oncternal Therapeutics, Inc. Common Stock position peaked at $215K in Q2 2013.
  • 58 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2013.

Based on Raymond James & Associates's 13F filing for Q3 2013, filed 13 Nov 2013.